Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spero Therapeutics ( (SPRO) ) has provided an announcement.
On August 12, 2025, Spero Therapeutics announced its second quarter 2025 financial results and provided a business update. The company reported a significant milestone in its PIVOT-PO Phase 3 trial for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which was stopped early for efficacy. Spero, in collaboration with GSK, plans to submit the data to the FDA in the second half of 2025. The company also highlighted its financial position, with cash and milestone payments expected to fund operations into 2028. Additionally, Spero reported a reduced net loss and increased revenue compared to the previous year, primarily due to collaboration revenue from GSK.
The most recent analyst rating on (SPRO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
Spero Therapeutics is currently facing significant financial and operational challenges, as evidenced by declining revenues, negative profit margins, and operational inefficiencies. Technical analysis suggests ongoing bearish momentum, while valuation metrics highlight financial struggles due to a negative P/E ratio. The earnings call highlighted promising developments in their tebipenem HBr program, but these are offset by setbacks in other trials and increased financial losses. The overall score reflects these mixed but predominantly negative factors.
To see Spark’s full report on SPRO stock, click here.
More about Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need.
Average Trading Volume: 4,550,015
Technical Sentiment Signal: Buy
Current Market Cap: $123M
For an in-depth examination of SPRO stock, go to TipRanks’ Overview page.